株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

幹細胞治療市場:治療方法別(自家、同種異系)、治療応用別(CNS、CVS、GIT、創傷治療、筋骨格、眼、免疫系) - 法規制環境、パイプライン分析および世界市場予測

Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020

発行 MarketsandMarkets 商品コード 300935
出版日 ページ情報 英文 196 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
幹細胞治療市場:治療方法別(自家、同種異系)、治療応用別(CNS、CVS、GIT、創傷治療、筋骨格、眼、免疫系) - 法規制環境、パイプライン分析および世界市場予測 Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020
出版日: 2014年04月23日 ページ情報: 英文 196 Pages
概要

世界の幹細胞治療市場は、自家幹細胞治療と同種幹細胞治療に分けられます。同種幹細胞治療は2015年に市場の最大のシェアを獲得すると予測されており、2015〜2020年にかけ最大でCAGR40%で拡大するとみられています。治療への応用では、眼病、代謝性疾患、筋骨格障害、免疫系疾患、中枢神経系疾患などがあります。中でも免疫系が最大のシェアを有していますが、今後中枢神経系疾患の分野で急速に発展すると期待されています。

当レポートでは、幹細胞治療市場の概要と業界動向とともに、治療方法別、治療応用別、地域別の動向、および参入企業のプロファイルをまとめ、概略下記の構成で取り上げております。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場動向

  • イントロダクション
  • 促進因子
  • 阻害因子
  • 機会
  • 課題
  • 成功戦略
  • 課題

第4章 パイプライン分析

第5章 投資家ネットワーク

第6章 治療方法別

  • イントロダクション
  • 同種幹細胞治療市場:用途別
    • イントロダクション
    • 眼病
    • 胃腸疾患
    • 免疫系疾患
    • 代謝性疾患
    • 筋骨格障害
    • 中枢神経系疾患
    • CVS疾患
    • 創傷
    • その他
  • 自家幹細胞治療市場:用途別
    • イントロダクション
    • 胃腸疾患
    • 中枢神経系疾患
    • 筋骨格障害
    • 創傷
    • CVS疾患
    • その他

第7章 治療分野別

  • イントロダクション
  • 眼病
  • 胃腸疾患
  • 免疫系疾患
  • 代謝性疾患
  • 筋骨格障害
  • 中枢神経系疾患
  • CVS疾患
  • 創傷
  • その他

第8章 法規制環境

第9章 地域別分析

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第10章 競合環境

  • 概要
  • 競合動向

第11章 企業プロファイル

  • Aastrom Biosciences Inc.
  • Advanced Cell Technologies, Inc.
  • Athersys Inc.
  • Celgene Corporation
  • Cellular Dynamics International
  • Cytori Therapeutics, Inc.
  • Fibrocell Science, Inc.
  • Gamida Cell Ltd.
  • Mesoblast Ltd.
  • Pluristem Therapeutics Inc.
  • Stemcells Inc.

図表

目次
Product Code: PH 2438

The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market.

In this report, the global stem cell therapy market has been segmented on the basis of mode of therapy (allogeneic and autologous stem cell therapy) and therapeutic applications (eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others). The allogeneic stem cell therapy market is expected to hold the largest share of the global stem cell therapy market by 2015. This large share can be attributed to the launch of the first-in-class stem cell therapy called prochymal (Osiris Therapeutics, Inc., U.S.), for the treatment of acute graft-versus-host disease (GVHD) in children. This allogeneic therapy was approved in New Zealand and Canada, in May 2012.

Additionally, allogeneic stem cell therapy market is expected to grow at a higher CAGR as compared to the autologous stem cell therapy. Factors such as wider therapeutic applications, easier production scale up, and larger number of ongoing clinical trials of allogeneic stem cell therapies compared to autologous stem cell therapies are stimulating its market growth.

Geographically, North America is forecasted to command the largest share of the global stem cell therapy market in 2015, followed by Asia-Pacific. A number of factors such as extensive government funding and increasing grant of orphan drug status for stem cell therapeutics by FDA, and presence of major leading companies are driving the growth of the stem cell therapy market in North America. However, the economic slowdown and unfavorable reimbursement scenario for the stem cell therapy constraints the growth of the market in this region. The Asia-Pacific region is poised to grow at the highest CAGR in the next five years. Factors such as huge patient population base, increasing regulatory support through favorable government policies, strong product pipeline of stem cell therapies, and rising licensing activities are propelling the growth of the stem cell therapy market in the Asia-Pacific region.

Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are adopting several growth strategies such as new product approvals, partnerships/agreements/collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysis-industry analysis (pipeline analysis and investor's network), regulatory scenario, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high growth segments of the stem cell therapy market, high-growth regions and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities. The above mentioned market research data, current market size, and forecast of future trends will help existing players and new entrants to make the necessary decisions regarding the product offerings, geographic focus, change in strategic approach, R&D investments for innovation in products and technologies, and levels of output in order to remain successful.

Companies purchasing the report could use any one or combination of the below mentioned five strategies for reaping the market share.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on stem cell therapy pipeline product portfolio offered by the top players in the stem cell therapy market. The report analyzes the products market by category/end user across geographies
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals in the stem cell therapy market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various stem cell therapy products across geographies
  • Market Diversification: Exhaustive information about pipeline products, targeted disease area, untapped geographies, recent developments, and investments in the stem cell therapy market
  • Competitive Assessment: In-depth assessment of market shares for pipeline products, strategies, targeted disease area, distribution networks, and manufacturing capabilities of leading players in the stem cell therapy market

Table of Contents

1 Introduction

  • 1.1 Objectives
  • 1.2 Markets Covered
  • 1.3 Stakeholders
  • 1.4 Market Size Estimation
    • 1.4.1 Market Definition
    • 1.4.2 Market Scope
  • 1.5 Research Methodology
    • 1.5.1 Secondary Research
    • 1.5.2 Primary Research
    • 1.5.3 Analysis & Output
    • 1.5.4 Assumptions
    • 1.5.5 Limitations
    • 1.5.6 Key Data Points Taken From Secondary Sources
    • 1.5.7 Key Data Points Taken From Primary Sources

2 Executive Summary

3 Market Dynamics

  • 3.1 Introduction
  • 3.2 Drivers
    • 3.2.1 Increasing Funding for New Stem Cell Lines
    • 3.2.2 Development of Advanced Genomic Methods for Stem Cell Analysis
    • 3.2.3 Increasing Focus on Human Embryonic Stem Cells
    • 3.2.4 Increasing Approvals of Clinical Trials for Stem Cells Therapy
  • 3.3 Restraints
    • 3.3.1 Lack of Required Infrastructures
    • 3.3.2 Difficulties Related With The Preservation of Stem Cells
    • 3.3.3 Ethical Issues Related to Embryonic Stem (ES) Cell
    • 3.3.4 Immunorejection After Stem Cell Transplantation
    • 3.3.5 Complexity Involved in Identification of Stem Cells in Adult Tissues
  • 3.4 Opportunities
    • 3.4.1 Lack of Effective Treatments to Cure Diseases
    • 3.4.2 Evolution of New Stem Cell Therapies
    • 3.4.3 Emergence of Induced Pluripotent Stem (IPS) Cells As An Alternative to Escs
    • 3.4.4 Emerging Markets Unfolds New Avenues Due to Low Regulatory Barriers and Clinical Trial Cost
  • 3.5 Challenges
    • 3.5.1 Dearth of Reimbursements
    • 3.5.2 High Costs Incurred in Stem Cell Processing
    • 3.5.3 Need of Automated Cell Culturing
    • 3.5.4 Lack of Clear Regulatory Guidelines
  • 3.6 Winning Imperatives
    • 3.6.1 Partnering With Academic Institutes
    • 3.6.2 Collaborating With Giant Pharmaceutical Firms
    • 3.6.3 High Focus on Emerging Markets
  • 3.7 Burning Issues
    • 3.7.1 Establishment of Safety Profiles
    • 3.7.2 Granting Orphan Drug Status to Stem Cell Therapeutics

4 Pipeline Analysis

5 Investor Network

6 By Mode of Therapy

  • 6.1 Introduction
  • 6.2 Allogeneic Stem Cell Therapy Market, By Application
    • 6.2.1 Introduction
    • 6.2.2 Eye Diseases
    • 6.2.3 GIT Diseases
    • 6.2.4 Immune System Diseases
    • 6.2.5 Metabolic Diseases
    • 6.2.6 Musculoskeletal Disorders
    • 6.2.7 CNS Diseases
    • 6.2.8 CVS Diseases
    • 6.2.9 Wounds and Injuries
    • 6.2.10 Other Diseases
  • 6.3 Autologous Stem Cell Therapy Market, By Application
    • 6.3.1 Introduction
    • 6.3.2 GIT Diseases
    • 6.3.3 CNS Diseases
    • 6.3.4 Musculoskeletal Disorders
    • 6.3.5 Wounds and Injuries
    • 6.3.6 CVS Diseases
    • 6.3.7 Other Diseases

7 By Therapeutic Applications

  • 7.1 Introduction
  • 7.2 Eye Diseases
  • 7.3 GIT Diseases
  • 7.4 Immune System Diseases
  • 7.5 Metabolic Diseases
  • 7.6 Musculoskeletal Disorders
  • 7.7 CNS Diseases
  • 7.8 CVS Diseases
  • 7.9 Wounds and Injuries
  • 7.10 Other Diseases

8 Regulatory Landscape

  • 8.1 North America
  • 8.2 Asia-Pacific
  • 8.3 Europe
  • 8.4 ROW (Rest of The World)

9 By Geography

  • 9.1 Introduction
  • 9.2 North America
  • 9.3 Europe
  • 9.4 Asia-Pacific
  • 9.5 ROW (Rest of The World)

10 Competitive Landscape

  • 10.1 Overview
  • 10.2 Competitive Situation & Trends

11 Company Profiles

  • 11.1 Aastrom Biosciences Inc.
  • 11.2 Advanced Cell Technologies, Inc.
  • 11.3 Athersys Inc.
  • 11.4 Celgene Corporation
  • 11.5 Cellular Dynamics International
  • 11.6 Cytori Therapeutics, Inc.
  • 11.7 Fibrocell Science, Inc.
  • 11.8 Gamida Cell Ltd.
  • 11.9 Mesoblast Ltd.
  • 11.10 Pluristem Therapeutics Inc.
  • 11.11 Stemcells Inc.

List of Tables

  • Table 1 Global Market, By Mode of Therapy, 2013-2020 ($Million)
  • Table 2 Investor Network for Stem Cell Therapy Market: Private and Government Investments
  • Table 3 Investor Network Market: Private and Government Investments
  • Table 4 Investor Network Market: Government Investments
  • Table 5 Global Market, By Mode of Therapy, 2013-2020 ($Million)
  • Table 6 Global Market, By Geography, 2013-2020 ($Million)
  • Table 7 Global Allogeneic Stem Cell Therapy Market, By Application, 2013-2020 ($Million)
  • Table 8 Global Allogeneic Stem Cell Therapy Market, By Geography, 2013-2020 ($Million)
  • Table 9 Allogeneic Stem Cell Therapy Market for Eye Diseases, By Geography, 2013-2020 ($Million)
  • Table 10 Allogeneic Market for GIT Diseases, By Geography, 2013-2020 ($Million)
  • Table 11 Allogeneic Market for Immune System Diseases, By Geography, 2013-2020 ($Million)
  • Table 12 Allogeneic Market for Metabolic Diseases, By Geography, 2013-2020 ($Million)
  • Table 13 Allogeneic Market for Musculoskeletal Disorders , By Geography, 2013-2020 ($Million)
  • Table 14 Allogeneic Market for CNS Diseases, By Geography, 2013-2020 ($Million)
  • Table 15 Allogeneic Market for CVS Diseases, By Geography, 2013-2020 ($Million)
  • Table 16 Allogeneic Market for Wounds & Injuries, By Geography, 2013-2020 ($Million)
  • Table 17 Allogeneic Market for Other Diseases, By Geography, 2013-2020 ($Million)
  • Table 18 Global Autologous Stem Cell Therapy Market, By Application, 2013-2020 ($Million)
  • Table 19 Global Autologous Market, By Geography, 2013-2020 ($Million)
  • Table 20 Autologous Market for GIT Diseases, By Geography, 2013-2020 ($Million)
  • Table 21 Autologous Market for CNS Diseases, By Geography, 2013-2020 ($Million)
  • Table 22 Autologous Market for Musculoskeletal Disorders , By Geography, 2013-2020 ($Million)
  • Table 23 Autologous Market for Wounds & Injuries, By Geography, 2013-2020 ($Million)
  • Table 24 Autologous Market for CVS Diseases, By Geography, 2013-2020 ($Million)
  • Table 25 Autologous Market for Other Diseases, By Geography, 2013-2020 ($Million)
  • Table 26 Global Stem Cell Therapy Market, By Application, 2013-2020 ($Million)
  • Table 27 Stem Cell Therapy Market for Eye Diseases, By Geography, 2013-2020 ($Million)
  • Table 28 Market for GIT Diseases, By Geography, 2013-2020 ($Million)
  • Table 29 Market for Immune System Diseases, By Geography, 2013-2020 ($Million)
  • Table 30 Market for Metabolic Diseases, By Geography, 2013-2020 ($Million)
  • Table 31 Market for Musculoskeletal Disorders, By Geography, 2013-2020 ($Million)
  • Table 32 Market for CNS Diseases, By Geography, 2013-2020 ($Million)
  • Table 33 Market for CVS Diseases, By Geography, 2013-2020 ($Million)
  • Table 34 Market for Wounds & Injuries, By Geography, 2013-2020 ($Million)
  • Table 35 Market for Other Diseases, By Geography, 2013-2020 ($Million)
  • Table 36 Regulatory Landscape In U.S. - Fda Guidance Documents
  • Table 37 North America: Market, By Mode of Therapy, 2013-2020 ($Million)
  • Table 38 North America: Market, By Therapeutic Application, 2013-2020 ($Million)
  • Table 39 North America: Market, By Allogeneic Therapeutic Application, 2013-2020 ($Million)
  • Table 40 North America: Market, By Autologous Therapeutic Application, 2013-2020 ($Million)
  • Table 41 Europe: Market, By Mode of Therapy, 2013-2020 ($Million)
  • Table 42 Europe: Market, By Therapeutic Application, 2013-2020 ($Million)
  • Table 43 Europe: Market, By Allogeneic Therapeutic Application, 2013-2020 ($Million)
  • Table 44 Europe: Market, By Autologous Therapeutic Application, 2013-2020 ($Million)
  • Table 45 Asia-Pacific: Market, By Mode of Therapy, 2013-2020 ($Million)
  • Table 46 Asia-Pacific: Market, By Therapeutic Application, 2013-2020 ($Million)
  • Table 47 Asia-Pacific: Market, By Allogeneic Therapeutic Application, 2013-2020 ($Million)
  • Table 48 Asia-Pacific: Market, By Autologous Therapeutic Application, 2013-2020 ($Million)
  • Table 49 ROW: Market, By Mode of Therapy, 2013-2020 ($Million)
  • Table 50 ROW: Market, By Therapeutic Application, 2013-2020 ($Million)
  • Table 51 ROW: Market, By Allogeneic Therapeutic Application, 2013-2020 ($Million)
  • Table 52 ROW: Market, By Autologous Therapeutic Application, 2013-2020 ($Million)
  • Table 53 Product Approvals
  • Table 54 Partnerships, Collaborations, & Agreements
  • Table 55 Partnerships, Collaborations, & Agreements
  • Table 56 Acquisitions
  • Table 57 Patents
  • Table 58 Other Developments

List of Figures

  • Figure 1 Market Segmentation, By Application
  • Figure 2 Market Segmentation, By Mode of Therapy
  • Figure 3 Pipeline Analysis, Based on Regulatory Authority, 2011-2013
  • Figure 4 Pipeline Analysis, Based on Country, 2011-2013
  • Figure 5 Pipeline Analysis, Based on Phase Under Clinical Trial, 2011-2013
  • Figure 6 Pipeline Analysis, Based on No. of Patients Enrolled, 2011-2013
  • Figure 7 Pipeline Analysis, Overall Therapy Based on Source of Cell Extraction, 2011-2013
  • Figure 8 Pipeline Analysis, Allogeinic Therapy Based on Clinical Trial Phases, 2011-2013
  • Figure 9 Pipeline Analysis, Autologous Therapy Based on Clinical Trial Phases, 2011-2013
  • Figure 10 Pipeline Analysis, By Application, 2011-2013
  • Figure 11 Pipeline Analysis, Allogeinic Therapy Based on Therapeutic Areas, 2011-2013
  • Figure 12 Pipeline Analysis, Autologous Therapy Based on Therapeutic Areas, 2011-2013
  • Figure 13 Overall Market: Based on Cell Lines Used, 2011-2013
  • Figure 14 Allogeneic Stem Cell Therapy Market: Based on Cell Lines Used, 2011-2013
  • Figure 15 Autologous Stem Cell Therapy Market: Based on Cell Lines Used, 2011-2013
  • Figure 16 Pipeline Analysis of Stem Cell Therapy Market: Based on Major Companies, 2011-2013
  • Figure 17 Investor Network for Stem Cell Therapy Market: Nih (U.S.) Funding
  • Figure 18 Market Segmentation, By Mode of Therapy
  • Figure 19 Comparison Between Allogeneic & Autologous Stem Cell Therapy Market
  • Figure 20 Estimated Cost Involved in The Manufacturing of Stem Cell Therapy Product
  • Figure 21 Allogeneic Stem Cell Therapy Market Segmentation, By Mode of Therapy
  • Figure 22 Autologous Stem Cell Therapy Market Segmentation, By Mode of Therapy
  • Figure 23 Market Segmentation, By Mode of Therapy
  • Figure 24 Stem Cell Therapy Process
  • Figure 25 Stem Cell Research Policies and Legislations
  • Figure 26 Geographic Distribution of CTG-Registered Stem Cell Therapy-Based Clinical Trials, 2000-2012
  • Figure 27 Evolution of Stem Cell Research, North America
  • Figure 28 Evolution of Stem Cell Research, Europe
  • Figure 29 Evolution of Stem Cell Research, Asia-Pacific
  • Figure 30 Key Growth Strategies, 2010-2014
  • Figure 31 Share of Key Companies in Patents Category, 2010-2014
  • Figure 32 Share of Key Companies in Product Approvals Category, 2010-2014
Back to Top